// App-Quantinova.ai

BSH19‐OR‐029 : Real‐World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Researchers

Presenter

  • E. Poynton

Principal Investigators

  • A. Alchawaf

  • S. Kassam

  • M. Horan

  • M. Rafferty

  • P. Kelsey

  • G. Scott

  • S. Bruce

  • H. Buckley

  • Y. Jer Lim

  • S. Johns

  • L. Ngu

  • R. Mcculloch

  • D. Lewis

  • T. Ajithkumar

  • D. Culligan

  • C. Rowntree

  • J. Wright

  • P. Mckay

  • S. Fourali

  • T.A. Eyre

  • J. Smith

  • W. Osborne

  • D. Yallop

  • K. Linton

  • K. Cwynarski

  • C. Fox

Medical Centers

  • University College Hospital, London,

  • Nottingham University hospital, U.K., Nottingham,

  • Christie Hospital, Manchester,

  • Kings College Hospital, London,

  • Newcastle Upon Tyne Hospitals NHS Trust, Newcastle

  • The Beatson, West of Scotland Cancer Centre, Glasgow,

  • Sheffield Teaching Hospitals, Sheffiled, UK

  • University Hospital of Wales, Cardiff, AK

  • Aberdeen Royal Infirmary, Aberdeen

  • Addenbrookes Hospital, Cambridge,

  • Aintree University Hospital, Liverpool

  • Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom

  • Plymouth Hospitals NHS Trust, Plymouth, UK

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Shared Authorship

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Primary central nervous system lymphoma

Biomarkers

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Methotrexate

  • Cytarabine liposomal

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved